GlassScriptPhysician profile
Scott C Hippeard
NPI 1073625109
$7,093.19
in general payments reported to CMS, 2019-2025
42 companies · $981 in 2025
The $981 reported for 2025 was more than what 91% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $983 · 2021: $818 · 2022: $960 · 2023: $1,006 · 2024: $1,117 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,079 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,078.72 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,138.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $738.87 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $668.06 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $474.45 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lundbeck LLC | $397.34 | 2020-2025 | Rexulti |
| Allergan, INC. | $356.76 | 2019-2020 | |
| Pfizer INC. | $346.83 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $324.94 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $286.77 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $243.20 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $137.85 | 2019-2022 | |
| Axsome Therapeutics, INC. | $120.26 | 2023-2025 | Sunosi, Auvelity |
| Supernus Pharmaceuticals, INC. | $119.37 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $118.93 | 2020-2025 | Livalo, Zoryve |
| Currax Pharmaceuticals LLC | $115.63 | 2022-2025 | Contrave, Nexletol, Onzetra Xsail |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hippeard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.